5th Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2020

The 5th Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2020 is dedicated to current challenges, best practices and the inside view of the future of Antibodies.

Topics

• Emerging discoveries, cutting-edge knowledge, tools, methods, and technologies to bring clinically safe and efficient Antibodies
• 360° view of Antibody from key industry players to leverage your business and scientific practice adoption
• Novel approaches and Antibody formats to accelerate Antibody therapeutics

Who should Attend

Attendees involved in:

• Manufacturing/CMC
• Antibody & Biologics Discovery /Development
• Molecular Biology
• Protein Engineering
• Antibody-drug conjugates (ADCs)
• Medicinal Chemistry
• Immunoconjugates
• Bioconjugates
• Maytansine
• Monoclonal antibodies (mAbs)
• Duocarmycin
• Tubulysins
• α-amanitin
• PBD-dimers
• Marine-based cytotoxins
• Topoisomerase inhibitors
• Peptide-drug conjugates
• Small-molecule drug conjugates
• Diabodies/Minibodies
• Nanoparticles/Nanobodies
• ADME
• PKPD
• Analytical & Formulation
• Toxicology
• Cancer
• Bioanalysis
• Hematology
• Oncology
• Biotherapeutics
• Antibody-based therapeutics
• Chemotherapeutics
• Immunotherapeutics